GleamWall
中文EN

NDRA ENDRA Life Sciences Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1681682 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY27.0%
TTM EPS YoY-126.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-217.7%
ROA-134.7%
ROIC (approx.)-360.8%
Asset turnover—

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio7.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$1.85M$3.19M
SG&A expense$3.72M$7.06M
Operating income-$5.76M-$10.82M
Pretax income-$7.03M-$11.51M
Income tax—$0
Net income-$7.03M-$11.51M
EBITDA-$5.72M-$10.77M
EPS (basic)-8.93-56.94
EPS (diluted)-8.93-56.94
Weighted avg. shares (diluted)787,020202,106
Balance sheet
Cash & equivalents$762,365$3.23M
Inventory$0$0
Current assets$967,969$3.43M
PP&E, net$42,516$69,281
Total assets$3.85M$4.45M
Current liabilities$750,956$605,230
Short-term debt—$0
Long-term debt—$0
Total debt—$0
Total liabilities$1.59M$1.89M
Shareholders' equity$2.26M$2.56M
Net debt—-$3.23M
Shares outstanding1.18M536,908
Cash flow statement
Operating cash flow-$5.18M-$7.40M
Capital expenditure$17,280$16,000
Free cash flow-$5.20M-$7.42M
Investing cash flow-$3.02M-$12,796
Financing cash flow$5.73M$7.81M
Depreciation & amortization$44,045$46,489
Stock-based compensation$329,409$571,924

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.